抗程序性死亡蛋白-1单药治疗晚期肢端黑色素瘤患者的应答模式影响
在五项前瞻性临床试验中接受抗PD-1单药治疗的晚期肢端黑色素瘤患者中,总缓解率为18.0%,疾病控制率为36.1%,中位无进展生存期为3.5个月(95%CI 1.7-5.3),中位总生存期为17.5个月(95%CI 15.1-19.9)。9.8%的患者符合超进展性疾病标准,预后显著更差。不同转移部位应答率不同,淋巴结最高(20.4%),肝脏最低(5.6%),异质性应答影响预后。
要点
- 抗PD-1单药治疗晚期肢端黑色素瘤的ORR为18.0%,DCR为36.1%。
- 9.8%的患者出现超进展性疾病,预后显著更差。
- 转移部位应答率不同:淋巴结20.4%,肝脏5.6%。
核心结论
- 免疫治疗期间出现超进展性疾病是晚期肢端黑色素瘤不良预后的重要生物标志物。
- 不同部位的转移灶对免疫治疗应答不同。
- 临床异质性应答影响患者结局。
- 构建的预测模型可区分肢端黑色素瘤免疫治疗后的预后。
研究设计与样本
- 在北京大学肿瘤医院五项抗PD-1单药治疗的前瞻性临床试验中接受治疗的晚期肢端黑色素瘤患者被纳入。
- 评估了个体转移灶的应答和异质性应答。
- 采用Cox比例风险回归分析识别可能的预测因素,并生成列线图预测1年和2年死亡风险。
主要发现
- 总缓解率为18.0%,疾病控制率为36.1%。
- 中位无进展生存期为3.5个月(95%CI 1.7-5.3),中位总生存期为17.5个月(95%CI 15.1-19.9)。
- 9.8%的患者符合超进展性疾病标准,其结局显著差于无超进展性疾病的患者。
- 共评估369个转移灶,缓解率最高为淋巴结(20.4%),最低为肝脏(5.6%)。
- 均匀缓解、异质性缓解和异质性或均匀进展的预后从好到差不同。
关键数值与推荐
- 总缓解率18.0%,疾病控制率36.1%。
- 中位无进展生存期3.5个月(95%CI 1.7-5.3),中位总生存期17.5个月(95%CI 15.1-19.9)。
- 超进展性疾病发生率为9.8%。
- 淋巴结转移灶缓解率20.4%,肝脏转移灶缓解率5.6%。
- 预测模型C指数训练集0.73(95%CI 0.63-0.84),验证集0.74(95%CI 0.61-0.86)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acral melanoma (AM) is less responsive to immunotherapy than nonacral cutaneous melanoma. Variable responses are seen during immunotherapy, including pseudoprogression, hyperprogressive disease (HPD) and heterogeneous responses. There are currently no studies on the response patterns of patients with AM treated with immunotherapy and the impact on the outcome. OBJECTIVES: To evaluate the response patterns and prognosis of patients with AM treated with anti-programmed death (PD)-1 antibodies. METHODS: Patients with advanced AM treated prospectively in five clinical trials of anti-PD-1 monotherapy at Peking University Cancer Hospital were included. Responses of individual metastases and heterogeneous responses were evaluated during immunotherapy. Cox proportional hazards regression analysis was conducted to identify the possible predictive factors and generate a nomogram to predict the risk of 1-year and 2-year mortality. RESULTS: The overall response rate was 18·0%, the disease control rate was 36·1%, median progression-free survival was 3·5 months [95% confidence interval (CI) 1·7-5·3] and median overall survival was 17·5 months (95% CI 15·1-19·9) for anti-PD-1 monotherapy. Overall, 9·8% of patients met the criteria of HPD, and displayed a dramatically worse outcome than patients without HPD. In total, 369 metastatic lesions were assessed, with the highest response rate in lymph nodes (20·4%) and the lowest in the liver (5·6%). Homogeneous response, heterogeneous response and heterogeneous or homogeneous progression had different prognoses from the best to the worst. A predictive model was constructed and achieved good accuracy with a C-index of 0·73 (95% CI 0·63-0·84) in the training set and 0·74 (95% CI 0·61-0·86) in the validation set. CONCLUSIONS: HPD during immunotherapy serves as an essential biomarker of poor prognosis in advanced AM. Metastases in different sites respond distinctively to immunotherapy. Clinically heterogeneous responses to immunotherapy affect the outcome of patients. A predictive model was built to distinguish the prognosis of acral melanoma under immunotherapy.
引用
- Zhou L, Shao L, Gao S, et al. Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy. Br J Dermatol. 2023. PMID: 36689499. doi:10.1093/bjd/ljac005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。